Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Denali Therapeutics (DNLI) Income from Continuing Operations (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Income from Continuing Operations for 9 consecutive years, with 128447000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations fell 12.0% to 128447000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 512438000.0, a 21.23% decrease, with the full-year FY2025 number at 512540000.0, down 21.23% from a year prior.
  • Income from Continuing Operations was 128447000.0 for Q4 2025 at Denali Therapeutics, down from 126902000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 183383000.0 in Q2 2023 to a low of 132970000.0 in Q1 2025.
  • A 5-year average of 85699750.0 and a median of 100577500.0 in 2023 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: soared 398.46% in 2023, then tumbled 154.0% in 2024.
  • Denali Therapeutics' Income from Continuing Operations stood at 75261000.0 in 2021, then tumbled by 31.11% to 98678000.0 in 2022, then tumbled by 34.38% to 132602000.0 in 2023, then grew by 13.51% to 114685000.0 in 2024, then dropped by 12.0% to 128447000.0 in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Income from Continuing Operations are 128447000.0 (Q4 2025), 126902000.0 (Q3 2025), and 124119000.0 (Q2 2025).